ApoE enhances nanodisk-mediated curcumin delivery to glioblastoma multiforme cells

Nanomedicine

Volumn 9, Issue 6, 2014, Pages 763-771

  Ghosh, Mistuni ^a,b   Ryan, Robert O ^a,b  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ApoE; apoptosis; confocal fluorescence microscopy; curcumin; glioblastoma; nanodisk

Indexed keywords

APOLIPOPROTEIN E; CURCUMIN; NANODISK; NANOPARTICLE; POLYPHENOL; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG CARRIER; NANOMATERIAL;

APOPTOSIS; ARTICLE; CELL NUCLEUS; CELL SURFACE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EXPOSURE; DRUG FORMULATION; DRUG TUMOR LEVEL; FLUORESCENCE; FLUORESCENCE MICROSCOPY; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; INTERNALIZATION; MOLECULAR INTERACTION; PRIORITY JOURNAL; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOLIPOPROTEINS E; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CURCUMIN; DRUG CARRIERS; GLIOBLASTOMA; HUMANS; NANOSTRUCTURES;

EID: 84901992121     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.13.35     Document Type: Article

References (29)

1. Ghosh M, Singh ATK, Xu W, Sulchek T, Gordon LI, Ryan RO. Curcumin nanodisks: formulation and characterization. Nanomedicine 7(2), 162-167 (2011).
2. Ryan RO. Nanodisks: hydrophobic drug delivery vehicle. Expert Opin. Drug Deliv. 5(3), 343-351 (2008). (Pubitemid 351454383)
3. Ryan RO. Nanobiotechnology applications of reconstituted high density lipoprotein. J. Nanobiotechnology 8, 28 (2010).
4. Oda MN, Hargreaves P, Beckstead JA, Redmond KA, van Antwerpen R, Ryan RO. Reconstituted high-density lipoprotein enriched with the polyene antibiotic, amphotericin B. J. Lipid Res. 47(2), 260-267 (2006). (Pubitemid 43276912)
5. Redmond KA, Nguyen TS, Ryan RO. All-trans retinoic acid nanodisks. Int. J. Pharm. 339(1-2), 246-250 (2007).
6. Epstein J, Sanderson IR, Macdonald TT. Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. Br. J. Nutr. 103(11), 1545-1557 (2010).
7. Spiller SE, Logsdon NJ, Deckard LA, Sontheimer H. Inhibition of nuclear factor kappa-B signaling reduces growth in medulloblastoma in vivo. BMC Cancer 11, 136 (2011).
8. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol. Pharm. 4(6), 807-818 (2007).
9. Schaffer M, Schaffer PM, Zidan J, Bar-Sela G. Curcuma as a functional food in the control of cancer and inflammation. Curr. Opin. Clin. Nutr. Metab. Care 14(6), 588-597 (2011).
10. Huang TY, Tsai TH, Hsu CW, Hsu YC. Curcuminoids suppress the growth and induce apoptosis through caspase-3- dependent pathways in glioblastoma multiforme (GBM) 8401 cells. J. Agric. Food Chem. 58(19), 10639-10645 (2010).
11. Senft C, Polacin M, Priester M, Seifert V, Kögel D, Weissenberger J. The nontoxic natural compound curcumin exerts anti-proliferative, anti-migratory, and anti-invasive properties against malignant gliomas. BMC Cancer 10, 491 (2010).
12. Zanotto-Filho A, Braganhol E, Edelweiss MI et al. The curry spice curcumin selectively inhibits cancer cells growth in vitro and in preclinical model of glioblastoma. J. Nutr. Biochem. 23(6), 591-601 (2012).
13. Perry MC, Demeule M, Regina A, Moumdjian R, Beliveau R. Curcumin inhibits tumor growth and angiogenesis in glioblastoma xenografts. Mol. Nutr. Food Res. 54(8), 1192-1201 (2010).
14. Singh ATK, Ghosh M, Forte TM, Ryan RO, Gordon LI. Curcumin nanodisk-induced apoptosis in mantle cell lymphoma. Leuk. Lymphoma 52(8), 1537-1543 (2011).
15. Ryan RO, Forte TM, Oda MN. Optimized bacterial expression of human apolipoprotein A-I. Protein Expr. Purif. 27(1), 98-103 (2003). (Pubitemid 37096475)
16. Fisher CA, Wang J, Francis GA, Sykes BD, Kay CM, Ryan RO. Bacterial overexpression, isotope enrichment and NMR analysis of the N-terminal domain of human apolipoprotein E. Biochem. Cell Biol. 75(1), 45-53 (1997). (Pubitemid 127733127)
17. Weisgraber KH, Rall SC Jr, Mahley RW, Milne RW, Marcel YL, Sparrow JT. Human apolipoprotein E. Determination of the heparin binding sites of apolipoprotein E3. J. Biol. Chem. 261(5), 2068-2076 (1986). (Pubitemid 17205129)
18. Kunwar A, Barik A, Pandey R, Priyadarsini KI. Transport of liposomal and albumin loaded curcumin to living cells: an absorption and fluorescence spectroscopic study. Biochim. Biophys. Acta 1760(10), 1513-1520 (2006). (Pubitemid 44428033)
19. Agrawal DK, Mishra PK. Curcumin and its analogues: potential anticancer agents. Med. Res. Rev. 30(5), 818-860 (2010).
20. Steck PA, Moser RP, Bruner JM et al. Altered expression and distribution of heparin sulfate proteoglycans in human gliomas. Cancer Res. 49(8), 2096-2103 (1989). (Pubitemid 19106521)
21. Maletínská L, Blakely EA, Bjornstad KA, Deen DF, Knoff LJ, Forte TM. Human glioblastoma cell lines: levels of low density lipoprotein receptor and low density lipoprotein receptor-related protein. Cancer Res. 60(8), 2300-2303 (2000). (Pubitemid 30225197)
22. Hauser PS, Narayanaswami V, Ryan RO. Apolipoprotein E: from lipid transport to neurobiology. Prog. Lipid Res. 50(1), 62-74 (2011).
23. Weisgraber KH, Mahley RW. Human apolipoprotein E: the Alzheimers disease connection. FASEB J. 10(13), 1485-1494 (1996). (Pubitemid 26384445)
24. Zsila F, Bikadi Z, Simonyi M. Circular dichroism spectroscopic studies reveal pH dependent binding of curcumin in the minor groove of natural and synthetic nucleic acids. Org. Biomol. Chem. 2(20), 2902-2910 (2004).
25. Nafisi S, Adelzadeh M, Norouzi Z, Sarbolouki MN. Curcumin binding to DNA and RNA. DNA Cell Biol. 28(4), 201-208 (2009).
26. Reuter S, Gupta SC, Park B, Goel A, Aggarwal BB. Epigenetic changes induced by curcumin and other natural compounds. Genes Nutr. 6(2), 93-108 (2011).
27. Stupp R, Mason WP, Van Den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987-996 (2005). (Pubitemid 40349501)
28. Dougherty JD, Fomchenko EI, Akuffo AA et al. Candidate pathways for promoting differentiation or quiescence in oligodendrocyte progenitor-like cells in glioma. Cancer Res. 72(18), 4856-4868 (2012).
29. Lima FR, Kahn SA, Soletti RC et al. Glioblastoma: therapeutic challenges, what lies ahead. Biochim. Biophys. Acta 1826(2), 338-349 (2012).